. The company’s pipeline consists of 4 scientific-stage therapies. Its most advanced drug prospect is ROS1 inhibitor taletrectinib for managing lung most cancers. Nuvation is finishing two section 2 pivotal reports on taletrectinib. The high-risk nature of these stocks means they will encounter significant price swings, normally driven by https://financefeeds.com/solana-price-forecast-ai-sets-sol-to-break-295-ath-in-one-month/